A COVID-19 vaccine developed and tested in Russia effectively generated an antibody reaction and showed no serious adverse effects, according to a friday published in the medical journal The Lancet.
Peer-reviewed knowledge can put Russia in the most career-sensitive race with the United States, Europe and China for the progression of an effective vaccine against the virus, Kirill Dmitriev, managing director of the Russian Direct Investment Fund, told Bloomberg. Friday that the country believes its progression is the “best in the world. “
“Russia has answered the questions that have been asked on this issue,” he said. “And we are convinced that we have the vaccine in the world. “
The test was conducted as a component of “two non-randomized phase 1/2 open studies in two Russian hospitals” and involved 76 healthy elderly volunteers aged 18 to 60. Volunteers had to isolate themselves after enrolling in the trial and remained in the hospital 28 days after vaccination, the vaccine uses two other human adenoviruses that have been modified to bring complex protein genes to the coronavirus in order to generate an immune response.
Preliminary effects of phase 1 and 2 trials indicated that the vaccine also triggered T-mobile responses within 28 days. T-mobiles are a type of white-blooded mobile that helps the immune formula fight infections.
Researchers compared post-vaccination immunity with the immune reaction other people had after COVID-19 herbal healing, and found that the antibody reaction is superior in vaccinated people, the study showed.
The Lancet also reported that there have been no adverse reactions to the vaccine, with maximum side effects not unusual for injection pain, fever, headache and muscle or joint pain.
Russia provoked a lot of skepticism when it announced that it had developed the world’s first approved COVID-19 vaccine in August, which President Vladimir Putin authorized before the vaccine completed three trials. Several high-level officials, such as Moscow Mayor Sergei Sobyanin and Defense Minister Sergei Shoigu, said they took the vaccine.
The review addressed several limitations in the trials, adding the absence of a placebo group; short follow-up time (42 days) Small number of participants and fairly young volunteers. It is not yet clear how the vaccine will affect the older and high-risk groups.
“Additional studies are needed to compare the vaccine in other populations, adding older groups, others with underlying medical situations, and others from at-risk groups,” the study says.
Russia approved phase 3 trials of the Sputnik V vaccine on 26 August, which will come with a larger organization of 40,000 volunteers from other age organizations and threats. Russian Health Minister Mikhail Murashko said in the past that the country would begin mass vaccinations in October and that doctors and teachers would be among the first to be vaccinated.
You’ve got four loose pieces left this month
To read, log in or create an account.
Find out why nearly a quarter of a million subscribers start their day with the 5.